尽管Ocular Therapeutix持续无利可图,但发现69.4M Q3亏损,但收入和收入估计数被抵消。 Ocular Therapeutix posted a $69.4M Q3 loss but beat revenue and earnings estimates despite ongoing unprofitability.

oclas Therapeutix报告说,2025年第三季度损失净额为6 940万美元,即每股38美分,调整后的损失略低于分析师的预期。 Ocular Therapeutix reported a third-quarter 2025 net loss of $69.4 million, or 38 cents per share, with adjusted losses slightly below analyst expectations. 收入达到1 450万美元,超过了预测的1 340万美元。 Revenue reached $14.5 million, exceeding the $13.4 million forecast. 该公司仍然无利可图,收入出现负增长,现金自由流通,但业绩超过收入估计数。 The company remains unprofitable, with negative revenue growth and free cash flow, but outperformed earnings estimates. 它推销DEXTENZA眼睛炎症,在与AffaMed治疗公司的伙伴关系的支持下,有较晚阶段的湿年龄肌肉畸形候选者。 It markets DEXTENZA for eye inflammation and has late-stage candidates for wet age-related macular degeneration, supported by a partnership with AffaMed Therapeutics. 尽管分析家乐观乐观不已,预计上扬92%,但股票仍面临早期生物技术公司典型的风险。 Despite strong analyst optimism and a projected 92% upside, the stock faces risks typical of early-stage biotech firms.